Symphony Health Announces Availability of 340B Drug Discount Program Data
14 December 2018 - 1:00AM
Symphony Health, a PRA Health Sciences company and a leading
provider of data, cloud-based analytics and consulting solutions to
life science companies and healthcare organizations, today
announces the availability of 340B Drug Discount Program data. This
data may be integrated directly into the company’s PHAST® NonRetail
Weekly and Monthly audits as well as NonRetailSource®, a
comprehensive offering incorporating indirect and direct drug sales
into institutions.
The 340B program comes from Section 340B of the Public Health
Service Act, which in essence places pharmaceutical manufacturers
in a pricing agreement with the government agency Health and Human
Services (HHS). Under the agreement, manufacturers provide
front-end discounts on covered outpatient drugs purchased by
specified providers known as “covered entities” that serve the
nation's most vulnerable patient populations.
As part of Symphony Health’s Enhanced Views program, which
brings expanded data assets and enhanced market measurement
capabilities to clients, the 340B Drug Discount data offers the
most comprehensive view of program activity to manufacturers today.
With tens of thousands of eligible covered entities, it would take
an individual manufacturer a great deal of time and effort to
collect data from these outlets, with limited visibility to the
full market. Symphony Health collects near census coverage of all
non-retail 340B activity from July 2016 to present, enabling
manufacturers to receive timely and accurate data on not only their
brands, but also competitor brands. Full and complete visibility to
340B data provides additional invoice transaction granularity -
enabling deeper, outlet-level contracting and access analyses which
help manufacturers to optimize their strategies in this important
market.
Key components of Symphony Health’s 340B Drug Discount data
within the PHAST® NonRetail audit include all products and markets
reported at class of trade, sub-class of trade and different
geographic levels as low as core-based statistical area (CBSA).
Within NonRetailSource®, data for client’s markets of interest are
reported at the individual outlet level across all 340B eligible
healthcare organizations, and reported at the individual
transaction level – across all products/forms/strengths.
For more information, visit Symphony Health or contact us at
solutions@symphonyhealth.com.
About Symphony Health: Symphony Health is a
leading provider of high-value data, analytics, and technology
solutions for biopharmaceutical manufacturers, healthcare
providers, and payers. The company helps clients understand disease
incidence, prevalence, progression, treatment and influences along
the patient and prescriber journeys by connecting and integrating a
broad set of primary and secondary data, and providing health
research, analytics and consulting expertise. Symphony Health
derived data improves health management decisions, and helps
clients drive revenue growth while providing critical insights on
how to effectively adapt to the changing healthcare ecosystem. For
more information, visit www.symphonyhealth.com.
About PRA Health Sciences:
PRA Health Sciences (NASDAQ:PRAH) is one of the world’s leading
global contract research organizations, or CROs, by revenue,
providing outsourced clinical development services to the
biotechnology and pharmaceutical industries. PRA’s global clinical
development platform includes more than 70 offices across North
America, Europe, Asia, Latin America, South Africa, Australia and
the Middle East and over 15,800 employees worldwide. Since 2000,
PRA has participated in approximately 3,700 clinical trials
worldwide. In addition, PRA has participated in the pivotal or
supportive trials that led to U.S. Food and Drug Administration or
international regulatory approval of more than 75 drugs. To learn
more about PRA, please visit www.prahs.com.
Media Contacts
Heather Varela
Symphony Health
Director, Marketing Communications
Heather.varela@symphonyhealth.com
(602) 463-7838
Roger Boutin
PRA Health Sciences, Inc.
Executive Director, Marketing
BoutinRoger@prahs.com
(434) 951-3924
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Oct 2024 to Nov 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Nov 2023 to Nov 2024